← Leaderboards
Sriram Sundaravel
University Of Chicago
$468,844
Attributed
$468,844
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $101.2K · FY2017–22$200K$150K$100K$50K$0
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$468,844 · 2
By mechanism
K00$378,776 · 1
F99$90,068 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Chicago
Same institution · by research overlap
- Chuan He$53,119,947
- Megan McNerney$6,106,581
- Tao Pan$13,229,930
- Michelle M Le Beau$39,023,275
- Xiaoxi Zhuang$15,074,334
Others in their field
Other Emerging Leaders on “Defect”
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$11,480,062
- Deanne Marie Taylor · National Disease Research Interchange$9,155,275
- Axel F Hoffmann · University Of Illinois At Urbana-Champaign$8,949,317
- Eva Morava-Kozicz · Mayo Clinic Rochester$8,480,790
- Paul Converti$7,107,161
- Allison Heath · Children'S Hosp Of Philadelphia$7,063,462
Research focus
DefectActin-Binding ProteinActinsCytokinesisBiochemicalAdducinBlood CellsAnemiaBaseCancer TherapyCd34 GeneCell LineCell PhysiologyCellsCell ShapeCell TypeBreast Cancer Cell LineChromosome 7q LossChromosome DeletionCancer InitiationClinical TrialsComorbidityCyclic Amp-Dependent Protein KinasesDifferential Expression
Grant awards (6)
Leveraging epigenetic and epitranscriptomic aberrations in cancer to identify molecular targets for designing therapy$101,228
K00 · FY2022 · CA · contact PI
Leveraging epigenetic and epitranscriptomic aberrations in cancer to identify molecular targets for designing therapy$96,602
K00 · FY2021 · CA · contact PI
Leveraging epigenetic and epitranscriptomic aberrations in cancer to identify molecular targets for designing therapy$91,976
K00 · FY2020 · CA · contact PI
Leveraging epigenetic and epitranscriptomic aberrations in cancer to identify molecular targets for designing therapy$88,970
K00 · FY2019 · CA · contact PI
Leveraging epigenetic and epitranscriptomic aberrations in cancer to identify molecular targets for designing therapy$44,524
F99 · FY2018 · CA · contact PI
Leveraging epigenetic and epitranscriptomic aberrations in cancer to identify molecular targets for designing therapy$45,544
F99 · FY2017 · CA · contact PI